Discussion
When I joined Bionews, the publisher of this website, in 2023 as a freelance sickle cell disease (SCD) columnist, I experienced something that stayed with me. As someone living with a rare disease, I wasn’t the only person like me in the workplace. Several colleagues also lived with chronic…
